Hermosillo

Researchers are evaluating the effects of the drug orforglipron compared with a placebo on cardiovascular outcomes in adults who have atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). This is a Phase 3, randomized, double-blind, placebo-controlled study designed to investigate major adverse cardiovascular events over a long period. Participants will receive either orforglipron or a placebo orally. The study is event-driven and will continue until the occurrence of major cardiovascular events or up to about 5 years. The treatments are administered without revealing to participants which group they are in to ensure unbiased results. During the study, participants will be monitored for the time to the first occurrence of a major cardiovascular event. Researchers will collect data from baseline through the end of the study, which lasts approximately 5 years. Regular assessments will help evaluate the safety and effects of the treatments on cardiovascular health in this population.

Researchers are evaluating whether ziltivekimab can help people who were hospitalized due to a heart attack by potentially reducing the development of heart disease and preventing new heart attacks or strokes. This Phase 3 study compares ziltivekimab with a placebo, which is a dummy medicine that has no effect on the body. Both treatments are given by chance, with equal likelihood for participants to receive either ziltivekimab or placebo. Participants will inject the study medicine once a month under the skin in the stomach, thigh, or upper arm. Ziltivekimab is given as an initial loading dose followed by monthly maintenance doses. The placebo group receives a matching injection schedule. The study duration is about two years. During the study, researchers will monitor participants for the time until the first serious heart-related event, including cardiovascular death, non-fatal heart attack, or non-fatal stroke. Participants will be closely observed from the start of randomization up to 25 months. The study includes regular follow-ups to assess safety and effectiveness of the treatments throughout this period.

Researchers are evaluating the impact of cool roof coatings on health, indoor environments, and economic outcomes in urban climate hotspots across the globe. This global multi-center cluster-randomized controlled trial focuses on communities in Ouagadougou (Burkina Faso), Ahmedabad (India), Tavua (Fiji), Niue, and Colima (Mexico) where extreme heat caused by climate change increases risks for heat-related illnesses and worsens physical, mental, and social health. The study aims to find effective passive housing adaptations to reduce heat stress and improve wellbeing in vulnerable populations living in poor housing conditions such as informal settlements and slums. The intervention being studied is the application of sunlight-reflecting cool roof coatings, which passively lower indoor temperatures by reflecting ultraviolet and visible sunlight and emitting absorbed solar heat. These coatings are applied to roofs in selected households to reduce heat exposure and energy use. The trial spans multiple urban hotspots with diverse climate and socioeconomic profiles, assessing the effects of cool roofs on health and environmental conditions over time. Participants will have their resting heart rate, blood glucose control, and depression levels measured repeatedly over 12 months, including during three consecutive hottest months and alternate months. Additional outcomes include indoor thermal comfort, blood pressure, dehydration, sleep quality, cognition, productivity, aggression, indoor air quality, energy expenditure, and healthcare utilization. The study will monitor these health and environmental indicators to determine the potential benefits of cool roofs in reducing heat stress and improving life quality in vulnerable communities.

Researchers are evaluating the effect of muvalaplin on reducing cardiovascular risk in adults with elevated lipoprotein(a) levels who either have atherosclerotic cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high Lp(a) levels and prior or potential cardiovascular events. The study aims to assess the time to the first major adverse cardiovascular event over about 5.25 years. Participants will be randomly assigned to receive either muvalaplin or a placebo, both administered orally. The study includes individuals with Lp(a) levels of at least 175 nanomoles per liter who have had a prior cardiovascular event within 10 years or are at risk for a first event due to conditions such as coronary artery disease, carotid stenosis, peripheral artery disease, high coronary artery calcium score, reduced kidney function with diabetes, or other high-risk factors. The treatment period lasts through the study duration, with close monitoring. During the study, participants will be regularly evaluated to track the occurrence of major adverse cardiovascular events, including heart attacks and strokes. Safety assessments will monitor blood pressure, kidney function, and heart failure status among other health indicators. The primary outcome measures the time to the first major cardiovascular event from baseline up to the end of the study, which spans approximately 5.25 years.